Key Findings from the Study
A current investigation indicates that innovative weight-reduction medications, including Ozempic and Zepbound, are capable of halving severe asthma flare-ups in adolescents carrying excess weight.
Researchers announced on December 29 in JAMA Network Open that teenagers using a GLP-1 medication required half as many emergency room treatments for asthma compared to those not on such drugs.
Potential Dual Advantages
The research group, under the guidance of Dr. Lin-Shien Fu, head of pediatric nephrology and immunology at Taichung Veterans General Hospital in Taiwan, stated that their results point to a possible combined benefit for this demographic. A single category of drug might tackle both weight regulation and decreased chances of asthma worsening, thus easing the load from two frequent and related long-term health issues.
Over a 12-month monitoring period, children on a GLP-1 drug experienced eight asthma-linked emergency visits, while those without weight-loss medication had 19 such incidents.
Reduction in Medication Needs
Adolescents on GLP-1 drugs were also less inclined to use steroids for asthma control, with 21% doing so versus 31% in the comparison group. Additionally, they needed rescue inhalers less frequently, at 32% compared to 45%.
Role of Weight Reduction
Dr. Michelle Katzow, director of the POWER Kids Weight Management Program and an associate professor of pediatrics at Cohen Children's Medical Center in New York City, noted that the loss of weight in these young people probably played a key role in enhancing their asthma condition.
She remarked in a news statement that the outcome isn't entirely unexpected, though the extent of weight loss triggered by the medication surpasses previous observations.
